Abstract:
INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.
journal_name
Expert Rev Neurotherjournal_title
Expert review of neurotherapeuticsauthors
Khan A,Corbett A,Ballard Cdoi
10.1080/14737175.2017.1326818subject
Has Abstractpub_date
2017-07-01 00:00:00pages
683-695issue
7eissn
1473-7175issn
1744-8360journal_volume
17pub_type
杂志文章,评审abstract::The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.4.465
更新日期:2005-07-01 00:00:00
abstract::Systemic thrombolysis with recombinant tissue plasminogen activator is the first therapy proven to be effective in acute ischemic stroke. Nevertheless, its efficacy and feasibility are still a matter of debate. Much of this debate derives from uncertainties regarding patient eligibility and problems implementing this ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.2.187
更新日期:2002-03-01 00:00:00
abstract::Parkinson's disease (PD) is characterized clinically by rest tremor, rigidity, bradykinesia and pathologically by degeneration of nigrostriatal dopamine neurons. Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of PD. Ongoing clinical and preclinical ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.868306
更新日期:2014-01-01 00:00:00
abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.6.831
更新日期:2005-11-01 00:00:00
abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.3.227
更新日期:2007-03-01 00:00:00
abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.47
更新日期:2012-06-01 00:00:00
abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2016.1202763
更新日期:2016-11-01 00:00:00
abstract:INTRODUCTION:The increasing development and availability of portable and wearable technologies is rapidly expanding the field of technology-based objective measures (TOMs) in neurological disorders, including Parkinson disease (PD). Substantial challenges remain in the recognition of disease phenomena relevant to patie...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2018.1530593
更新日期:2018-11-01 00:00:00
abstract::Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.5.647
更新日期:2002-09-01 00:00:00
abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.3.371
更新日期:2005-05-01 00:00:00
abstract:INTRODUCTION:Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Inde...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2020.1826931
更新日期:2020-12-01 00:00:00
abstract::Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,meta分析,评审
doi:10.1586/14737175.2015.1125783
更新日期:2016-01-01 00:00:00
abstract::Poor insight or unawareness of illness has been commonly observed in schizophrenia and has been long recognized as a potent barrier to treatment adherence and a risk factor for a range of poorer outcomes. Paradoxically, the achievement of insight often poses a different set of problems including depression and low sel...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2013.811150
更新日期:2013-07-01 00:00:00
abstract::Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2020.1729130
更新日期:2020-03-01 00:00:00
abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2015.988709
更新日期:2015-01-01 00:00:00
abstract::The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.863710
更新日期:2014-01-01 00:00:00
abstract::Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.144
更新日期:2012-12-01 00:00:00
abstract::Hypertension is an important risk factor for stroke. The latter results in disability and premature death and represents a major public health problem. Various studies have established a strong relationship between increasing blood pressure and stroke risk, as well as clear evidence of a reduction in the incidence of ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.6.2.203
更新日期:2006-02-01 00:00:00
abstract::Introduction: Neurocysticercosis (NCC) is the most common helminthic infection of the central nervous system and a global public health problem. However, its diagnosis is complicated since histological demonstration of the parasite is often not feasible, clinical manifestations are nonspecific, most neuroimaging findi...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2020.1707667
更新日期:2020-02-01 00:00:00
abstract::Advances in neuroscience have led to an expanded and improved understanding of neurobiological changes associated with rehabilitation and exercise in Parkinson's disease (PD). This knowledge has led to a direct clinical impact of increased referral for early and continuous exercise programs for individuals with PD (ph...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.43
更新日期:2011-06-01 00:00:00
abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2019.1621750
更新日期:2019-07-01 00:00:00
abstract::Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2013.865872
更新日期:2013-12-01 00:00:00
abstract::This article reviews the potential uses of complementary and alternative medicine (CAM) techniques for individuals with mood disorders. Mood disorders are among the most prevalent mental health issues today and there are many approaches towards their management. While many different types of medication are available, ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.77
更新日期:2011-07-01 00:00:00
abstract:INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2017.1359088
更新日期:2017-09-01 00:00:00
abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.13.17
更新日期:2013-03-01 00:00:00
abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2015.1028370
更新日期:2015-04-01 00:00:00
abstract::Millions of people worldwide suffer from diseases that result from a failure of central pathways to regulate behavioral and physiological processes. Advances in genetics and pharmacology have already allowed us to appreciate that rather than this dysregulation being systemic throughout the brain, it is usually rooted ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.948850
更新日期:2014-09-01 00:00:00
abstract::Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive therapy ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.51
更新日期:2010-06-01 00:00:00
abstract::Bipolar disorder is one of the most serious and prevalent psychiatric disorders. The aim of the present article is to review the efficiency of cognitive-behavioral therapy (CBT) for bipolar patients. Some studies show consistent evidence that cognitive therapy, concomitant to psycho-education and pharmacological treat...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.75
更新日期:2010-07-01 00:00:00
abstract::Median survival of patients with malignant glioma (MG) from time of diagnosis is approximately 1 year, despite surgery, irradiation and conventional chemotherapy. Improving patient outcome relies on our ability to develop more effective therapies that are directed against the unique molecular aberrations within a pati...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.116
更新日期:2009-12-01 00:00:00